Exousia Pro Officially Announces the Production of Plant-Based Exosomes Has Begun
Marijuana Inc. (OTC PINK:MAJI), operating as Exousia Pro, has officially begun production of mushroom-based exosomes at its Orlando lab. The company is utilizing licensed intellectual property from Progenycite to extract high-quality exosomes from mushrooms for skincare and wellness applications.
The company's product line will offer various exosome formulations targeting specific skincare needs, featuring benefits such as:
- Antioxidant effects from polyphenols and selenium
- Moisturizing properties from beta-glucan
- Anti-inflammatory effects from Vitamin B Complex
- Skin renewal properties from Vitamin D₂
- Brightening and anti-aging benefits from selenium, polyphenols, and niacin
CEO Michael Sheikh reported strong interest from multiple distributors and formulators, with sample production marking their first commercialization milestone. The company expects significant business growth and revenue recognition in the coming quarter.
Marijuana Inc. (OTC PINK:MAJI), operante come Exousia Pro, ha ufficialmente avviato la produzione di esosomi a base di funghi nel suo laboratorio di Orlando. L'azienda sta utilizzando proprietà intellettuale concessa in licenza da Progenycite per estrarre esosomi di alta qualità dai funghi per applicazioni di cura della pelle e benessere.
La linea di prodotti dell'azienda offrirà varie formulazioni di esosomi mirate a specifiche esigenze della pelle, con benefici come:
- Effetti antiossidanti da polifenoli e selenio
- Proprietà idratanti da beta-glucano
- Effetti antinfiammatori dal complesso di vitamina B
- Proprietà di rinnovamento della pelle dalla vitamina D₂
- Benefici schiarenti e anti-invecchiamento da selenio, polifenoli e niacina
Il CEO Michael Sheikh ha riportato un forte interesse da parte di più distributori e formulatori, con la produzione di campioni che segna il loro primo traguardo di commercializzazione. L'azienda prevede una significativa crescita aziendale e riconoscimento dei ricavi nel prossimo trimestre.
Marijuana Inc. (OTC PINK:MAJI), que opera como Exousia Pro, ha comenzado oficialmente la producción de exosomas a base de hongos en su laboratorio de Orlando. La empresa está utilizando propiedad intelectual licenciada de Progenycite para extraer exosomas de alta calidad de los hongos para aplicaciones de cuidado de la piel y bienestar.
La línea de productos de la empresa ofrecerá varias formulaciones de exosomas dirigidas a necesidades específicas de cuidado de la piel, con beneficios como:
- Efectos antioxidantes de polifenoles y selenio
- Propiedades hidratantes de beta-glucano
- Efectos antiinflamatorios del complejo de vitamina B
- Propiedades de renovación de la piel de la vitamina D₂
- Beneficios iluminadores y antienvejecimiento de selenio, polifenoles y niacina
El CEO Michael Sheikh informó un fuerte interés de múltiples distribuidores y formuladores, con la producción de muestras marcando su primer hito de comercialización. La empresa espera un crecimiento significativo en los negocios y reconocimiento de ingresos en el próximo trimestre.
Marijuana Inc. (OTC PINK:MAJI), Exousia Pro로 운영되는 이 회사는 올랜도 실험실에서 버섯 기반의 엑소좀 생산을 공식적으로 시작했습니다. 이 회사는 Progenycite의 라이센스가 부여된 지적 재산을 활용하여 스킨케어 및 웰빙 응용을 위한 고품질의 엑소좀을 버섯에서 추출하고 있습니다.
회사의 제품 라인은 특정 스킨케어 요구를 목표로 하는 다양한 엑소좀 포뮬레이션을 제공하며, 다음과 같은 이점을 특징으로 합니다:
- 폴리페놀과 셀레늄의 항산화 효과
- 베타-글루칸의 보습 특성
- 비타민 B 복합체의 항염 효과
- 비타민 D₂의 피부 재생 특성
- 셀레늄, 폴리페놀 및 니아신의 밝기 및 노화 방지 효과
CEO 마이클 셰이크는 여러 유통업체와 포뮬레이터로부터 강한 관심을 보고했으며, 샘플 생산이 그들의 첫 번째 상업화 이정표를 나타냅니다. 회사는 다음 분기에 상당한 사업 성장과 수익 인식을 기대하고 있습니다.
Marijuana Inc. (OTC PINK:MAJI), opérant sous le nom d'Exousia Pro, a officiellement commencé la production d'exosomes à base de champignons dans son laboratoire d'Orlando. L'entreprise utilise une propriété intellectuelle sous licence de Progenycite pour extraire des exosomes de haute qualité à partir de champignons pour des applications de soins de la peau et de bien-être.
La gamme de produits de l'entreprise proposera diverses formulations d'exosomes ciblant des besoins spécifiques en matière de soins de la peau, avec des avantages tels que :
- Effets antioxydants provenant des polyphénols et du sélénium
- Propriétés hydratantes provenant du bêta-glucane
- Effets anti-inflammatoires du complexe de vitamine B
- Propriétés de renouvellement de la peau de la vitamine D₂
- Avantages éclaircissants et anti-âge du sélénium, des polyphénols et de la niacine
Le PDG Michael Sheikh a rapporté un fort intérêt de la part de plusieurs distributeurs et formulateurs, la production d'échantillons marquant leur premier jalon de commercialisation. L'entreprise s'attend à une croissance significative des affaires et à une reconnaissance des revenus au cours du prochain trimestre.
Marijuana Inc. (OTC PINK:MAJI), das als Exousia Pro tätig ist, hat offiziell die Produktion von pilzbasierten Exosomen in seinem Labor in Orlando begonnen. Das Unternehmen nutzt lizenziertes geistiges Eigentum von Progenycite, um hochwertige Exosome aus Pilzen für Hautpflege- und Wellness-Anwendungen zu extrahieren.
Die Produktlinie des Unternehmens wird verschiedene Exosomenformulierungen anbieten, die auf spezifische Hautpflegebedürfnisse abzielen und Vorteile wie folgt bieten:
- Antioxidative Wirkungen durch Polyphenole und Selen
- Feuchtigkeitsspendende Eigenschaften durch Beta-Glucan
- Entzündungshemmende Wirkungen durch Vitamin B-Komplex
- Hauterneuerungseigenschaften durch Vitamin D₂
- Aufhellende und anti-aging Vorteile durch Selen, Polyphenole und Niacin
CEO Michael Sheikh berichtete von großem Interesse seitens mehrerer Distributoren und Formulierer, wobei die Produktion von Proben ihren ersten kommerziellen Meilenstein markiert. Das Unternehmen erwartet im kommenden Quartal ein signifikantes Wachstum und eine Umsatzanerkennung.
- Production of innovative skincare product has officially started
- Strong market demand reported with interest in billions of exosomes
- Revenue generation expected to begin next quarter
- Licensed IP from Progenycite provides technological advantage
- No current revenue from exosome production
- Product still in sample phase, pending client approval
- Success depends on successful integration into client formulations
Exousia Pro will be sending out samples to clients expected to place orders
ORLANDO, FL / ACCESS Newswire / March 25, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., announces the official start of production of its innovative mushroom-based exosomes at its Orlando lab. This marks a significant milestone in bringing cutting-edge skincare and wellness solutions to market.
Exousia Pro is leveraging licensed intellectual property from Progenycite to produce high-quality exosomes extracted from mushrooms. These exosomes capture the unique health benefits of each mushroom species, offering users a tailored selection of exosome formulations designed to support a variety of skincare needs. The company's product menu will allow clients to choose exosomes based on the specific properties of each mushroom, from antioxidant effects to moisturizing and anti-aging benefits.
The demand for Exousia Pro's products is already growing, with interest expressed in billions of exosomes. To ensure compatibility with their clients' formulations, Exousia Pro is sending out samples for evaluation. These samples will allow formulators to verify that the exosomes integrate seamlessly into their products without affecting consistency.
Below is a list of some of the benefits the exosomes manufactured by Exousia Pro will have.
1. Antioxidant Effects (Polyphenols, Selenium), • Protects skin cells from oxidative stress and free radical damage, • Helps prevent wrinkles, dark spots, and other signs of aging, • Supports skin brightening and an even skin tone
2. Moisturizing and Barrier-Strengthening (Beta-Glucan) • Beta-glucan is a powerful humectant that attracts moisture to the skin,• Reinforces the skin's natural barrier function, preventing water loss,• Soothes dry, sensitive, or irritated skin,• Helps improve skin elasticity and smoothness
3. Anti-Inflammatory and Soothing Effects (Vitamin B Complex, Beta-Glucan) • Niacin (Vitamin B3) helps reduce redness, irritation, and inflammation, • Supports acne-prone skin by controlling excess oil production, • Calms sensitive or reactive skin, promoting overall skin health
4. Skin Renewal and Repair (Vitamin D₂) • Vitamin D₂ promotes skin cell regeneration and turnover, • Helps maintain a healthy epidermis and strengthens skin immunity, • May improve skin's resilience against environmental stressors and UV damage, • Supports ceramide production for deeper hydration and barrier repair
5. Brightening and Anti-Aging (Selenium, Polyphenols, Niacin) • Helps reduce the appearance of dark spots and hyperpigmentation, • Supports collagen production for firmer, more youthful skin, • Provides anti-photoaging effects, protecting skin from UV-induced damage
"The commercialization of our business is ramping," said CEO of Marijuana Inc., Michael Sheikh. "We have strong interest from multiple distributors and formulators that have requested samples of our mushroom exosomes which are rich in a number of nutrients. Not all mushrooms are created equal and the exosomes and the healing properties they carry vary from variety to variety. Sample production is our first commercialization milestone, and we expect to grow the business significantly over the coming quarter and that includes the recognition of revenue."
About Us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
FAQ
What products has MAJI started manufacturing in March 2025?
What are the key benefits of MAJI's mushroom exosome products?
How is MAJI planning to commercialize its exosome products?
What is MAJI's revenue outlook for their exosome business?
